Exposure-Response Analysis to Assess the Concentration-QTc Relationship of Iberdomide.
Sign Up to like & getrecommendations! Published in 2023 at "Clinical pharmacology in drug development"
DOI: 10.1002/cpdd.1254
Abstract: Iberdomide is an orally available cereblon-modulating agent being developed for the treatment of hematologic malignancies and autoimmune-mediated diseases. To assess the potential concentration-QTc relationship in humans and to ascertain or exclude a potential QT effect… read more here.
Keywords: iberdomide; concentration; concentration qtc; analysis ... See more keywords
Evaluation of iberdomide and cytochrome p450 drug-drug interaction potential in vitro and in a phase 1 study in healthy subjects.
Sign Up to like & getrecommendations! Published in 2020 at "European journal of clinical pharmacology"
DOI: 10.1007/s00228-020-03004-w
Abstract: PURPOSE Iberdomide is a cereblon E3 ligase modulator capable of redirecting the protein degradation machinery of the cell towards the elimination of target proteins potentially driving therapeutic effects. In vitro studies demonstrated that iberdomide predominantly… read more here.
Keywords: iberdomide; drug; study healthy; healthy subjects ... See more keywords